Drug Database
DI

diphtheria-tetanus vaccine (GC 1107 / GC1107)

✓ Approved

GC Biopharma · · 疫苗

什么是 diphtheria-tetanus vaccine?

diphtheria-tetanus vaccine 是一种疫苗,由GC Biopharma研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intramuscular (IM) Injection。

药物档案

商品名GC 1107, GC1107
公司GC Biopharma
药物类别疫苗
分子靶点,
给药途径Injectable (Others), Intramuscular (IM) Injection
状态Approved

作用机制

分子靶点

diphtheria-tetanus vaccine 作用于 2 个分子靶点:

()
()
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

diphtheria-tetanus vaccine 针对 2 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsDiphtheria✓ Approved
Infections and infestationsTetanus✓ Approved

相关研究文献

PubMedGeriatrie et psychologie neuropsychiatrie du vieillissement2026-11-17

[2026 vaccination schedule for adults aged 65 years and older: towards comprehensive vaccine-based prevention in older age].

Corroyer-Simovic Bénédicte B

The 2026 French vaccination schedule redefines geriatric prevention, extending its focus beyond the prevention of infectious diseases to the preservation of independence and functional health. Yet vaccination coverage in France remains inadequate. To address immunosenescence, the strategy prioritizes comprehensive protection against respiratory infections caused by influenza viruses, SARS-CoV-2, pneumococcus and respiratory syncytial virus (RSV). For influenza, guidelines recommend the preferential use of enhanced vaccines-either high-dose or adjuvanted formulations-to improve protection in older adults and reduce hospital admissions. Covid-19 boosters remain essential for this vulnerable population, with the adjuvanted recombinant protein vaccine Nuvaxovid® available alongside mRNA vaccines. Pneumococcal prevention is considerably simplified: a single dose of the 21-valent pneumococcal conjugate vaccine (PCV21, Capvaxive®) is recommended for all adults aged 65 years and older. This vaccine covers the serotypes responsible for 83.5% of invasive pneumococcal disease cases in France in 2024. RSV vaccination is indicated for adults aged 75 years and older and for those aged 65 years and older with cardiopulmonary comorbidities, providing protection against severe disease and reducing hospital admissions during winter. Beyond respiratory infections, vaccination against herpes zoster with the adjuvanted recombinant vaccine Shingrix® is recommended for all adults aged 65 years and older. Recent data associate this vaccination not only with the prevention of postherpetic neuralgia but also with a reduced risk of stroke. Tdap-IPV boosters remain essential in the context of recent pertussis epidemics and the persistent risk of tetanus in older adults. Vaccine coadministration is safe and should be offered to improve coverage and reduce the number of visits required. When vaccination records are unavailable, the priority is to proceed with vaccination rather than delay protection. This proactive, integrated approach aims to address inadequate vaccination coverage, reduce mortality and preserve independence in older adults.

PMID 43042679
阅读全文 →
PubMedJournal of clinical immunology2026-11-17

SIMPATHY Study: Specific Antibody Response to Typhim Vi Polysaccharide as a Surrogate Marker of Infectious Risk in Secondary Immunodeficiency Associated with B Cell Cancer.

Peixoto-Rodriguez Alejandro A, Melero Josefa J, de Andrés Ana A, López-Granados Eduardo E et al.

Recurrent and severe infections represent a major cause of morbidity and mortality of secondary immunodeficiency (SID) associated with B-cell lymphoproliferative syndromes (B-CLPD). Nevertheless, immunological evaluation and prophylactic interventions are often delayed until infectious complications occur. Early vaccination is therefore relevant not only because it provides protection during the initial phases of B-CLPD, but also because it enables the identification of patients at higher risk of infection. In this context, assessment of antigen-specific humoral response has been proposed as a useful biomarker for identifying patients with greater clinical vulnerability. We conducted SIMPATHY (Secondary Immunodeficiency Multicentric study on the Antibody Production to Typhi vaccine), a multicentre, retrospective, observational study including 128 individuals with B-CLPD, classified according to the presence or absence of severe and/or recurrent infections, as well as healthy controls. Specific IgG antibody responses to Streptococcus pneumoniae (13-valent conjugate, Prevenar), Salmonella typhi (Typhim Vi), and tetanus toxoid vaccines were assessed at baseline and 4-weeks after vaccination. Among 128 individuals analysed, patients with B-CLPD showed significant immunological and clinical differences compared to healthy controls, particularly in vaccine-specific antibody responses and lymphocyte subsets. B-CLPD patients with recurrent or severe infections exhibited markedly reduced pre-vaccination anti-pneumococcal (p = 0.03) and post-vaccination anti-pneumococcal (p = 0.001) and anti-Salmonella typhi Vi titers (p = 0.1), highlighting impaired vaccine-specific antibody responses as potential predictors of infection risk. An immunological classification identified two subgroups within B-CLPD, predominant antibody defect and combined immune defect, with a trend toward higher respiratory infection rates in the latter, suggesting broader immune dysfunction.

PMID 43040101
阅读全文 →
PubMedBMC infectious diseases2026-11-17

Clinical characteristics and indicators associated with poor in-hospital prognosis among children with severe pertussis in Shandong Province, China (2022-2024).

Wang Ping P, Li Jian J

Pertussis is a life-threatening respiratory infection among young infants. This retrospective study enrolled only children already diagnosed with severe pertussis. We aimed to describe clinical characteristics and identify indicators associated with poor in‑hospital prognosis within this severe cohort, rather than exploring predictors for progression from mild to severe pertussis. A retrospective observational study was conducted among 80 children diagnosed with severe pertussis who were hospitalized between January 2022 and December 2024. Clinical data, laboratory results, treatment, and outcomes were collected. Multivariate logistic regression and receiver operating characteristic (ROC) curve analysis were applied to screen indicators associated with composite poor in-hospital prognosis and evaluate their prognostic performance.Composite poor in-hospital prognosis was defined as new in-hospital adverse events including invasive mechanical ventilation, pertussis encephalopathy with persistent neurological sequelae, or all-cause in-hospital death; 6 out of 80 participants met this composite endpoint. White blood cell count was included as a continuous variable in multivariate regression. The optimal cutoff of > 30 × 10⁹/L was derived from ROC analysis for descriptive and potential bedside reference only and was not used for regression modelling. The median age was 4 months and 19 days (range, 1 month 14 days to 5 years); 65.0% (52/80) of patients were infants ≤ 3 months who could not receive routine diphtheria, pertussis, and tetanus (DPT) vaccine. All patients presented paroxysmal cough, and 95% had inspiratory whoop. Leukocytosis (WBC > 20 × 10⁹/L) was observed in 45.0% of children; 75.0% had patent foramen ovale (PFO), and 18.80% developed secondary cardiac abnormalities. Erythromycin combination therapy carried a significantly higher risk of liver dysfunction than monotherapy (36.40% vs. 8.60%, P < 0.05). Multivariate logistic regression identified three independent correlates of composite poor prognosis: unvaccinated status (OR = 4.2, 95%CI 1.8-9.6, P = 0.001), mixed bacterial-viral co-infection (OR = 3.5, 95%CI 1.2-10.1, P = 0.023), and elevated continuous white blood cell count (OR = 5.1, 95%CI 2.3-11.4, P < 0.001). Given the limited number of poor-prognosis events (n = 6), these adjusted associations should be interpreted cautiously as exploratory findings.ROC analysis using continuous WBC count yielded an AUC of 0.678, whereas the combined prognostic model derived from multivariable logistic regression achieved an AUC of 0.689. Infants aged ≤ 3 months constituted the majority of children hospitalized with severe pertussis. After adjusting for age-related vaccination eligibility, unvaccinated status, mixed bacterial-viral co-infection, and higher white blood cell count were independently associated with poor in-hospital prognosis. ROC analysis demonstrated only modest discriminative performance of these indicators; at present, they serve merely as potential references and require external validation before any clinical application. Not applicable.

PMID 43040268
阅读全文 →
PubMedFood chemistry: X2026-11-17

Identification of fresh and aged green tea based on Raman-autofluorescence spectral fusion and machine learning: from laboratory analysis towards field application.

He Zongtai Z, Yang Guiyan G, He Zhangjin Z, Cao Fengjing F et al.

High market premiums incentivize the fraudulent substitution of fresh green tea with aged leaves. Conventional analytical methods lack rapid, in situ, and nondestructive capabilities. In this study, we present an identification method for fresh and aged green tea based on the synergy of dual-modal Raman- autofluorescence spectroscopy. Spectra from fresh and aged samples were acquired by confocal micro-Raman and handheld Raman spectrometers. Homologous feature fusion was performed on the extracted Raman and autofluorescence signals, and classification models were constructed using five machine learning algorithms. Results demonstrate that dual-modal fusion significantly enhances classification performance. Specifically, the one-dimensional convolutional neural network (1D-CNN) achieved the optimal accuracies of 96.25% and 97.97% for the confocal micro-Raman and handheld devices, respectively. By leveraging the cross-modal synergy on the handheld equipment, this fusion strategy establishes a viable pathway for transitioning green tea quality assessment from laboratory analysis to rapid, in situ, and nondestructive field applications.

PMID 43041927
阅读全文 →
PubMedBMC public health2026-11-17

Post-introduction evaluation of COVID-19 vaccine deployment in Ghana: lessons learnt to inform future new vaccine introductions and strengthen public health readiness, 2023.

Amponsa-Achiano Kwame K, Shen Angela K AK, Baiden Laryea Eunice E, Carlton Julie Garon JG et al.

On March 2nd, 2021, Ghana, the first country to receive vaccines from the COVAX facility, began its COVID-19 vaccination using a complex multi-phased approach, to reach target populations. We evaluated the vaccine deployment to document best practices challenges and lessons for future new vaccine introductions and public health emergency readiness. We conducted a mixed methods post-introduction evaluation, purposively sampling 36 facilities from 12 districts in six regions. Adapting the World Health Organization's COVID-19 Post-Introduction Evaluation tool, we conducted a cross-sectional survey using a structured questionnaire, reviewed programme records, observed practices, and interviewed purposively selected health workers, immunization managers and partners who supported vaccine deployment. We performed summary descriptive statistics on quantitative data, thematic analysis on qualitative data, and triangulated the results. As of March 2023, more than 70% of the target population (15 years and older) had received at least one dose, while more than 50% had completed the primary series. Vaccine deployment was built on the existing immunisation programme and functional coordinating bodies. Cold chain capacity was revamped with ultra-low-temperature freezers, while 33.3% of surveyed districts adjusted waste disposal systems to accommodate COVID-19 vaccine introduction. Door-to-door delivery and demand generation through varied risk communication and community engagement strategies improved vaccine access. Electronic data platforms were established, surge capacity improved, and healthcare and community workers were trained. Initial unpredictable vaccine supplies limited vaccination efforts. Changing vaccine information affected health workers' ability to engage communities with up-to-date guidance. While vaccine safety monitoring systems were in place, reporting knowledge varied among health workers, and 36% of surveyed facilities had ever documented and reported COVID-19 vaccine-related adverse events following immunisation. Challenges with electronic data systems limited timely access to and use of granular service-delivery data for decision-making. Ghana leveraged existing immunisation and emergency-response systems to make substantial progress in COVID-19 vaccine deployment. Coordination, cold chain expansion, flexible service delivery, demand generation and workforce mobilisation supported implementation. Irregular vaccine supply, data system challenges, variable adverse event reporting, waste management pressure and misinformation challenged deployment. These findings provide lessons for adult immunisation, life-course vaccination and future public health emergency readiness.

PMID 43040294
阅读全文 →
PubMedSmall (Weinheim an der Bergstrasse, Germany)2026-11-17

Alginate-DNA Core-Shell Hydrogel Microspheres Program Antigen Release Kinetics for Potent Single-Dose Subunit Vaccination.

Shen Fengyun F, Yan Lingling L, Sun He H, Wu Junjie J et al.

Conventional vaccine sustained release strategies exhibit monophasic antigen kinetics that fail to align with the temporal order of T and B cell activation, limiting single-dose efficacy. Using a protein-carrier peptide vaccine model, we designed an alginate-DNA core-shell hydrogel microsphere that programmed differential antigen release kinetics through orthogonal loading mechanisms. Physical encapsulation enabled carrier protein release within 3 days to prime T cells, while DNA cross-linking sustained epitope-carrier protein conjugate release over 11 days to drive B cell responses, achieving a release interval exceeding 8 days that orchestrates sequential T and B cell activation. In a single immunization, this strategy induces significantly higher epitope-specific IgG titers compared to formulations with either co-rapid or co-sustained release. A SARS-CoV-2 peptide vaccine based on our strategy elicits substantially stronger humoral immunity than traditional aluminum-adjuvanted vaccines. This work establishes orthogonal loading-mediated kinetic programming as a versatile platform for next-generation single-injection subunit vaccines.

PMID 43042745
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多diphtheria-tetanus vaccine